FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126845260> ?p ?o ?g. }

• W3126845260 endingPage "170" @default.
• W3126845260 startingPage "165" @default.
• W3126845260 abstract "Objectives The use of granulocyte colony-stimulating factors (G-CSF) during concurrent chemo-radiotherapy (cCTRT) for small cell lung cancer is not recommended by the American Society of Clinical Oncology due to safety concerns. This secondary analysis explored the safety and the role of prophylactic G-CSF (proG-CSF) in the delivery of cCTRT. Material and methods Secondary analysis of 487 patients treated as per protocol on the phase 3 CONVERT trial which randomized patients between once-daily RT or twice-daily. Results 180 of 487 eligible patients (37 %) received proG-CSF, 60 (33 %) as primary prophylaxis and 120 (67 %) as secondary prophylaxis following myelotoxic events. The regimen incidence of febrile neutropenia (FN) was 22 %. Its incidence in the proG-CSF group reduced significantly when proG-CSF was administered (22 % vs 10 %; OR 0.4; 95 %CI 0.2−0.7; p = 0.002). The rate of blood transfusion was higher in the proG-CSF group (51 % vs 31 %; OR 2.4; 95 %CI 1.6–3.5; p < 0.001). The incidence of severe thrombocytopenia was also higher is this group (28 % vs 15 %; OR 2.2; 95 %CI 1.4–3.5; p = 0.001). But this was significantly higher in those on secondary vs primary prophylaxis (34 % vs 15 %; OR 2.9; 95 %CI 1.3–7.4 p = 0.009) No differences observed in RT-related toxicity, treatment-related mortality or any survival outcomes. The optimal dose intensity (85 % or higher) of cisplatin was achieved in more patients within the proG-CSF group (75 % vs 67 %; OR 1.5; 95 %CI 0.9–2.3; p = 0.056). Conclusion There was no evidence that G-CSF directly caused myelotoxicity, instead most patients started G-CSF due to higher myelotoxicity risk. G-CSF maintained the planned dose intensity and there was no detrimental effect on survival. G-CSF may be considered as a supportive measure in this setting." @default.
• W3126845260 created "2021-02-15" @default.
• W3126845260 creator A5003892829 @default.
• W3126845260 creator A5007868555 @default.
• W3126845260 creator A5025013953 @default.
• W3126845260 creator A5036282459 @default.
• W3126845260 creator A5039103158 @default.
• W3126845260 creator A5040285878 @default.
• W3126845260 creator A5048550515 @default.
• W3126845260 creator A5089954905 @default.
• W3126845260 date "2021-03-01" @default.
• W3126845260 modified "2023-10-18" @default.
• W3126845260 title "Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial" @default.
• W3126845260 cites W1804059878 @default.
• W3126845260 cites W1900393559 @default.
• W3126845260 cites W1905406155 @default.
• W3126845260 cites W1969996363 @default.
• W3126845260 cites W2014184159 @default.
• W3126845260 cites W2046463525 @default.
• W3126845260 cites W2110645520 @default.
• W3126845260 cites W2141539943 @default.
• W3126845260 cites W2323020638 @default.
• W3126845260 cites W2341745217 @default.
• W3126845260 cites W2408045437 @default.
• W3126845260 cites W2699278758 @default.
• W3126845260 cites W2891815598 @default.
• W3126845260 cites W2984188227 @default.
• W3126845260 cites W3048696092 @default.
• W3126845260 doi "https://doi.org/10.1016/j.lungcan.2021.01.025" @default.
• W3126845260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33545577" @default.
• W3126845260 hasPublicationYear "2021" @default.
• W3126845260 type Work @default.
• W3126845260 sameAs 3126845260 @default.
• W3126845260 citedByCount "9" @default.
• W3126845260 countsByYear W31268452602021 @default.
• W3126845260 countsByYear W31268452602022 @default.
• W3126845260 countsByYear W31268452602023 @default.
• W3126845260 crossrefType "journal-article" @default.
• W3126845260 hasAuthorship W3126845260A5003892829 @default.
• W3126845260 hasAuthorship W3126845260A5007868555 @default.
• W3126845260 hasAuthorship W3126845260A5025013953 @default.
• W3126845260 hasAuthorship W3126845260A5036282459 @default.
• W3126845260 hasAuthorship W3126845260A5039103158 @default.
• W3126845260 hasAuthorship W3126845260A5040285878 @default.
• W3126845260 hasAuthorship W3126845260A5048550515 @default.
• W3126845260 hasAuthorship W3126845260A5089954905 @default.
• W3126845260 hasBestOaLocation W31268452602 @default.
• W3126845260 hasConcept C120665830 @default.
• W3126845260 hasConcept C121332964 @default.
• W3126845260 hasConcept C126322002 @default.
• W3126845260 hasConcept C141071460 @default.
• W3126845260 hasConcept C143998085 @default.
• W3126845260 hasConcept C168563851 @default.
• W3126845260 hasConcept C2776256026 @default.
• W3126845260 hasConcept C2776694085 @default.
• W3126845260 hasConcept C2777063308 @default.
• W3126845260 hasConcept C2777767877 @default.
• W3126845260 hasConcept C2778850193 @default.
• W3126845260 hasConcept C2781413609 @default.
• W3126845260 hasConcept C509974204 @default.
• W3126845260 hasConcept C61511704 @default.
• W3126845260 hasConcept C71924100 @default.
• W3126845260 hasConcept C90924648 @default.
• W3126845260 hasConceptScore W3126845260C120665830 @default.
• W3126845260 hasConceptScore W3126845260C121332964 @default.
• W3126845260 hasConceptScore W3126845260C126322002 @default.
• W3126845260 hasConceptScore W3126845260C141071460 @default.
• W3126845260 hasConceptScore W3126845260C143998085 @default.
• W3126845260 hasConceptScore W3126845260C168563851 @default.
• W3126845260 hasConceptScore W3126845260C2776256026 @default.
• W3126845260 hasConceptScore W3126845260C2776694085 @default.
• W3126845260 hasConceptScore W3126845260C2777063308 @default.
• W3126845260 hasConceptScore W3126845260C2777767877 @default.
• W3126845260 hasConceptScore W3126845260C2778850193 @default.
• W3126845260 hasConceptScore W3126845260C2781413609 @default.
• W3126845260 hasConceptScore W3126845260C509974204 @default.
• W3126845260 hasConceptScore W3126845260C61511704 @default.
• W3126845260 hasConceptScore W3126845260C71924100 @default.
• W3126845260 hasConceptScore W3126845260C90924648 @default.
• W3126845260 hasFunder F4320319985 @default.
• W3126845260 hasFunder F4320334576 @default.
• W3126845260 hasLocation W31268452601 @default.
• W3126845260 hasLocation W31268452602 @default.
• W3126845260 hasLocation W31268452603 @default.
• W3126845260 hasOpenAccess W3126845260 @default.
• W3126845260 hasPrimaryLocation W31268452601 @default.
• W3126845260 hasRelatedWork W1984271822 @default.
• W3126845260 hasRelatedWork W2027339718 @default.
• W3126845260 hasRelatedWork W2037087317 @default.
• W3126845260 hasRelatedWork W2114989931 @default.
• W3126845260 hasRelatedWork W2147791919 @default.
• W3126845260 hasRelatedWork W2256530687 @default.
• W3126845260 hasRelatedWork W2399166583 @default.
• W3126845260 hasRelatedWork W2410418099 @default.
• W3126845260 hasRelatedWork W2413360557 @default.
• W3126845260 hasRelatedWork W4386416976 @default.
• W3126845260 hasVolume "153" @default.
• W3126845260 isParatext "false" @default.

• next